CALY-001 is a fully human monoclonal antibody inhibiting Matrix Metalloproteinase 9 (MMP-9).

MMP-9 degrades extracellular matrix (ECM) proteins and processes a number of bioactive molecules. MMP-9 is involved in several biological pathways, such as cell migration, angiogenesis, inflammation, tissue remodeling and fibrosis. As a result, MMP-9 is an attractive target for multiple pathologies, from auto-immune and inflammatory diseases to fibrotic diseases and cancers. CALY-001 has a mode of action distinct from that of GS-5745, an anti-MMP-9 monoclonal antibody currently developed by Gilead Sciences.




CALY-002 is a humanized monoclonal antibody inhibiting Interleukin-15 (IL-15).

IL-15 is a cytokine mainly expressed by monocytes, dendritic cells and epithelial cells. IL-15 plays multiple roles in the immune system, especially in the gastro-intestinal tract, by controlling the homeostasis and activation of T, B, and NK cells. CALY-002 is well positioned as paradigm-changing, first-in-class treatment, for several niche gastrointestinal indications with currently no approved treatment.